Ouabain Effects on Human Anaplastic Thyroid Carcinoma 8505C Cells
Authors:
- Mariana Pires TeixeiraMTMariana Pires Teixeira
- Natalia Ferreira HaddadNHNatalia Ferreira Haddad
- Eliza Freitas PassosEPEliza Freitas Passos
- Marcelle Novaes AndradeMAMarcelle Novaes Andrade
- Maria Luisa Arantes CamposMCMaria Luisa Arantes Campos
- Joyle Moreira Carvalho da SilvaJSJoyle Moreira Carvalho da Silva
- Camila Saggioro de FigueiredoCFCamila Saggioro de Figueiredo
- Elizabeth Giestal-De-AraujoEGElizabeth Giestal-De-Araujo
- Denise Pires de CarvalhoDCDenise Pires de Carvalho
- Leandro Miranda-AlvesLeandro Miranda-Alves
- Luciana Souza de PaivaLPLuciana Souza de Paiva
Open Access
Abstract
Anaplastic thyroid carcinoma (ATC) is a rare, but aggressive, carcinoma derived from follicular cells. While conventional treatments may improve patients’ survival, the lethality remains high. Therefore, there is an urgent need for more effective ATC treatments. Cardiotonic steroids, such as ouabain, have been shown to have therapeutic potential in cancer treatment. Thus, we aimed to evaluate ouabain’s effects in human anaplastic thyroid cells. For this, 8505C cells were cultured in the presence or absence of ouabain. Viability, cell death, cell cycle, colony formation and migratory ability were evaluated in ouabain-treated and control 8505C cells. The expression of differentiation and epithelial-to-mesenchymal transition (EMT) markers, as well as IL-6, TGFb1 and their respective receptors were also quantified in these same cells. Our results showed that ouabain in vitro decreased the number of viable 8505C cells, possibly due to an inhibition of proliferation. A reduction in migration was also observed in ouabain-treated 8505C cells. In contrast, decreased mRNA levels of PAX8 and TTF1 differentiation markers and increased levels of the N-cadherin EMT marker, as well as IL-6 and TGFb1, were found in ouabain-treated 8505C cells. In short, ouabain may have anti-proliferative and anti-migratory effect on 8505C cells, but maintains an aggressive and undifferentiated profile.Keywords
Funding Information
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/010.002198/2019, E-26/200.798/2021)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (303288/2019-1)
- Pró-Reitoria de Pesquisa, Pós-Graduação e Inovação, Universidade Federal Fluminense
This publication has 45 references indexed in Scilit:
- Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cellsBiomedicine & Pharmacotherapy, 2016
- mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenibOncotarget, 2015
- A Novel Dual AMPK Activator/mTOR Inhibitor Inhibits Thyroid Cancer Cell GrowthThe Journal of Clinical Endocrinology & Metabolism, 2015
- Ouabain elicits human glioblastoma cells apoptosis by generating reactive oxygen species in ERK-p66SHC-dependent pathwayMolecular and Cellular Biochemistry, 2014
- Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathwaysThe International Journal of Biochemistry & Cell Biology, 2012
- Quantitative High-Throughput Drug Screening Identifies Novel Classes of Drugs with Anticancer Activity in Thyroid Cancer Cells: Opportunities for RepurposingThe Journal of Clinical Endocrinology & Metabolism, 2012
- The Functional Interaction between the Paired Domain Transcription Factor Pax8 and Smad3 Is Involved in Transforming Growth Factor-β Repression of the Sodium/Iodide Symporter GeneJournal of Biological Chemistry, 2004
- TGF-β control of rat thyroid follicular cells differentiationMolecular and Cellular Endocrinology, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Lack of responsiveness to TGF-β1 in a thyroid carcinoma cell line with functional type I and type II TGF-β receptors and Smad proteins, suggests a novel mechanism for TGF-β insensitivity in carcinoma cellsMolecular and Cellular Endocrinology, 1999